We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CORT Stock Rises 42% in a Month: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
Corcept plans to resubmit relacorilant's NDA for Cushing's syndrome after a prior FDA CRL.
Lifyorli won FDA approval for platinum-resistant ovarian cancer, with sales likely to start in Q2 2026.
CORT's Lifyorli approval is expected to broaden the company's revenue base beyond Korlym.
Shares of Corcept Therapeutics (CORT - Free Report) have risen 41.8% in the past month, driven by encouraging progress with its proprietary, selective cortisol modulator, relacorilant, which is being developed for Cushing’s syndrome.
Last month, the company announced that it would resubmit the new drug application (NDA) for relacorilant in Cushing’s syndrome. Last December, the FDA issued a complete response letter (“CRL”) to the NDA for relacorilant for the given indication.
The company is planning to resubmit the NDA for relacorilant for treating Cushing’s syndrome shortly. The FDA has informed that the Prescription Drug User Fee Act (PDUFA) date would be approximately six months after the resubmission of the NDA.
Year to date, shares of Corcept have rallied 113.3% against the industry’s decline of 9.2%.
Image Source: Zacks Investment Research
CORT’s Relacorilant Approved for Ovarian Cancer
In March 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. Following the nod, Lifyorli became the first FDA-approved selective glucocorticoid receptor antagonist for the given indication.
Corcept has also submitted a marketing authorization application to the European Medicines Agency, seeking approval for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. A final decision in Europe is expected by the end of 2026.
The FDA nod for Lifyorli was a significant milestone for Corcept, as it is expected to diversify the company’s revenue stream beyond Korlym, which is approved for treating Cushing's syndrome. The company is likely to record Lifyorli sales from the second quarter of 2026.
CORT Aims to Diversify With Lifyorli
The approval of Lifyorli should help diversify the company’s revenue base and reduce its reliance on Korlym, which has been its sole source of revenues.
Korlym recorded sales of $164.9 million, up around 5% year over year, driven by rising demand.
Reflecting the growing momentum with Korlym and other business activities, Corcept raised its full-year 2026 revenue guidance to $950 million-$1.05 billion during the first quarter of 2026. The company previously expected total revenues in the range of $900 million to $1 billion in 2026.
Relacorilant, in combination with other anticancer therapies, is also being studied for treating other solid tumors, including platinum-sensitive ovarian, prostate, endometrial, cervical and pancreatic cancers.
The consistent growth of Korlym revenues, coupled with the upcoming first sales of Lifyorli and the promising advancement of relacorilant in Cushing’s syndrome, positions Corcept for continued growth. These catalysts are likely to support the company’s long-term growth prospects and should maintain positive momentum in the stock.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share (EPS) have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV shares have risen 4.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 79.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 18.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
CORT Stock Rises 42% in a Month: Here's What You Should Know
Key Takeaways
Shares of Corcept Therapeutics (CORT - Free Report) have risen 41.8% in the past month, driven by encouraging progress with its proprietary, selective cortisol modulator, relacorilant, which is being developed for Cushing’s syndrome.
Last month, the company announced that it would resubmit the new drug application (NDA) for relacorilant in Cushing’s syndrome. Last December, the FDA issued a complete response letter (“CRL”) to the NDA for relacorilant for the given indication.
The company is planning to resubmit the NDA for relacorilant for treating Cushing’s syndrome shortly. The FDA has informed that the Prescription Drug User Fee Act (PDUFA) date would be approximately six months after the resubmission of the NDA.
Year to date, shares of Corcept have rallied 113.3% against the industry’s decline of 9.2%.
Image Source: Zacks Investment Research
CORT’s Relacorilant Approved for Ovarian Cancer
In March 2026, the FDA approved Lifyorli (relacorilant) in combination with nab-paclitaxel for the treatment of adult patients with platinum-resistant ovarian cancer. Following the nod, Lifyorli became the first FDA-approved selective glucocorticoid receptor antagonist for the given indication.
Corcept has also submitted a marketing authorization application to the European Medicines Agency, seeking approval for relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer. A final decision in Europe is expected by the end of 2026.
The FDA nod for Lifyorli was a significant milestone for Corcept, as it is expected to diversify the company’s revenue stream beyond Korlym, which is approved for treating Cushing's syndrome. The company is likely to record Lifyorli sales from the second quarter of 2026.
CORT Aims to Diversify With Lifyorli
The approval of Lifyorli should help diversify the company’s revenue base and reduce its reliance on Korlym, which has been its sole source of revenues.
Korlym recorded sales of $164.9 million, up around 5% year over year, driven by rising demand.
Reflecting the growing momentum with Korlym and other business activities, Corcept raised its full-year 2026 revenue guidance to $950 million-$1.05 billion during the first quarter of 2026. The company previously expected total revenues in the range of $900 million to $1 billion in 2026.
Relacorilant, in combination with other anticancer therapies, is also being studied for treating other solid tumors, including platinum-sensitive ovarian, prostate, endometrial, cervical and pancreatic cancers.
The consistent growth of Korlym revenues, coupled with the upcoming first sales of Lifyorli and the promising advancement of relacorilant in Cushing’s syndrome, positions Corcept for continued growth. These catalysts are likely to support the company’s long-term growth prospects and should maintain positive momentum in the stock.
Corcept Therapeutics Incorporated Price
Corcept Therapeutics Incorporated price | Corcept Therapeutics Incorporated Quote
CORT's Zacks Rank & Stocks to Consider
Corcept currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Indivior Pharmaceuticals (INDV - Free Report) , Liquidia Corporation (LQDA - Free Report) and Immunocore (IMCR - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Indivior Pharmaceuticals’ 2026 earnings per share (EPS) have increased from $3.33 to $4.05. Over the same period, EPS estimates for 2027 have risen from $3.66 to $4.27. INDV shares have risen 4.8% year to date.
Indivior Pharmaceuticals’ earnings beat estimates in each of the trailing four quarters, with the average surprise being 65.44%.
Over the past 60 days, estimates for Liquidia’s 2026 EPS have increased to $2.97 from $1.50. Over the same period, EPS estimates for 2027 have risen to $4.81 from $2.91. LQDA shares have surged 79.3% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 54.40%.
Over the past 60 days, estimates for Immunocore’s 2026 have improved from a loss of 88 cents per share to earnings of 6 cents. Over the same period, EPS estimates for 2027 have risen from 24 cents to 87 cents. IMCR shares have lost 18.5% year to date.
Immunocore’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 46.66%.